Globenewswire·2025-12-06 13:00Core Insights - Disc Medicine, Inc. presented positive initial data from the RALLY-MF Phase 2 trial of DISC-0974 for treating anemia in myelofibrosis (MF) at the ASH Annual Meeting, showing significant reductions in hepcidin and increases in iron levels, leading to clinically meaningful improvements in anemia across various patient types [1][2]. Group 1: Trial Results - The ongoing Phase 2 trial enrolled 47 adult patients with MF and anemia, with 34 patients included in the responder analysis [2]. - DISC-0974 treatment resulted in over 75% reduction in hepcidin and significant increases in serum iron [6]. - 63% of non-transfusion dependent (nTD) patients achieved a hemoglobin increase of ≥1 g/dL for ≥12 weeks, while 50% had an increase of ≥1.5 g/dL for ≥12 weeks [6]. - 71% of low transfusion burden patients achieved transfusion independence over a 16-week period [6]. - 67% of high transfusion burden patients achieved a ≥50% reduction in transfusion requirement [6]. - 50% of patients receiving concomitant JAK inhibitor therapy achieved a major hematologic response [6]. Group 2: Treatment Administration and Tolerability - DISC-0974 was administered subcutaneously at a dose of 50 mg every 4 weeks for up to 6 treatments [2]. - The treatment was generally well-tolerated, with diarrhea and urinary tract infections being the only related adverse events reported in two or more subjects [6]. Group 3: Future Plans and Developments - The company plans to advance the DISC-0974 program to address the unmet need for anemia treatment in MF, as there are currently no approved therapies for this condition [2]. - Additional data from the trial is expected to be shared in the second half of 2026 [6].